CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Detail)

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019	May 31, 2019	Jan. 28, 2020	May 22, 2019	Nov. 08, 2018	May 31, 2010	Apr. 30, 2010
Summary Of Significant Accounting Policies [Line Items]
Net loss	$ (35,767,729)	$ (14,860,468)	$ (16,163,999)	$ (12,573,811)	$ (66,792,196)	$ (41,292,761)
Accumulated (deficit)	(296,683,031)				(296,683,031)		$ (229,363,407)
Balance in excess of federally insured limits	$ 7,100,000				7,100,000		3,300,000
Impairment charges					$ 0	0
Pre-launch inventory qualified for capitalization							$ 0
Estimated future unvested forfeitures					0.00%
Common stock, shares authorized	700,000,000				700,000,000		700,000,000
Preferred Stock Shares authorized to be issued	5,000,000				5,000,000		5,000,000
Treasury stock, par value	$ 0.001				$ 0.001
Treasury stock, shares					286,008
Amortization of discount on convertible notes	$ 0			559,383	$ 1,469,625	676,917
Amortization of debt issuance costs					$ 404,340	$ 175,024
Federal statutory income tax rate, percent					21.00%	28.62%
Common stock options and warrants to purchase					173,185,971	175,043,638
Income Tax Expense (Benefit)	0			$ 0	$ 0	$ (2,826,919)
Prostagene Llc [Member]
Summary Of Significant Accounting Policies [Line Items]
Income Tax Expense (Benefit)					2,800,000
Equity Securities
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs	$ 2,300,000				2,300,000		$ 4,300,000
Short-Term Convertible Notes
Summary Of Significant Accounting Policies [Line Items]
Direct costs associated with the convertible notes							1,000,000
Amortization of debt issuance costs					400,000	200,000
Short-Term Convertible Notes \| Detachable Common Stock Warrants
Summary Of Significant Accounting Policies [Line Items]
Debt discount							$ 4,200,000
Amortization of discount on convertible notes					$ 1,500,000	$ 700,000
Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized												100,000,000
Preferred Stock Shares authorized to be issued	400,000				400,000		400,000				400,000
Preferred stock, shares outstanding	92,100				92,100		92,100
Series C Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Preferred stock, shares outstanding	8,203				8,203
Common Stock
Summary Of Significant Accounting Policies [Line Items]
Common shares issued upon conversion of preferred stock					28,386,571	921,000
Common shares issued upon conversion of debt securities					8,108,305	10,658,690
Series D Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Preferred Stock Shares authorized to be issued	11,737				11,737		11,737	11,737
Preferred stock, shares outstanding	7,570				7,570		0	7,570
Maximum
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized									700,000,000	600,000,000
Preferred Stock Shares authorized to be issued	5,000,000				5,000,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized									600,000,000	450,000,000